We have various drugs in key therapeutics areas such as biosimilars, novel cancer drugs and diagnostics.
Innogene Kalbiotech provides targeted therapy in the treatment of cancer using an innovative monoclonal antibody. Our humanized monoclonal antibody has been approved in more than 30 countries for various indications such as adult and paediatric giloma, head and neck cancer, nasopharyngeal cancer, and pancreatic cancer.
The antibody has been commercialized in most of the ASEAN countries. It has also been granted orphan drug status by US FDA and EMEA for Glioma and pancreatic cancer treatment.
We also offer several biosimilar products, which are commercialized in most ASEAN countries, Kalbiotech has demonstrated a consistent ability to source the cost-effective biopharmaceuticals from across the globe to serve the unmet needs and growing demand of Asia.